A Phase 1 interventional study of BGM0504 and BGM0504 in Non-diabetic Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing BGM0504 in Obesity — none open to participants now, none under way, none of them phase 3. BGM0504 · Obesity.
Among the 10 studies testing BGM0504 in Obesity, this one is the 5th largest by enrollment, is one of 6 that started in 2025, is one of 6 in phase 1, and was the 7th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →None of the 10 studies testing BGM0504 in Obesity is open now. The open studies under Obesity, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 6 started in 2025.
This study's enrollment of 80 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 78 across the 10 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 3 most frequent:
BrightGene Bio-Medical Technology Co., Ltd. is the lead sponsor of 18 studies on the registry; 3 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd.: none open now, none under way, none of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd., this one is the 5th largest by enrollment, is one of 8 that started in 2025, is one of 8 in phase 1, and was the 7th registered.
BrightGene Bio-Medical Technology Co., Ltd.’s Obesity studies by the year they started, since 2023.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing BGM0504 in Obesity, from their registry updates:
Among BrightGene Bio-Medical Technology Co., Ltd.’s 11 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(BMI) meeting one of the following requirements:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mg BGM0504 administered orally
Drug: BGM0504
40 mg BGM0504 administered orally
Drug: BGM0504
60 mg BGM0504 administered orally
Drug: BGM0504
Placebo administered orally
Drug: Placebo
80mg BGM0504 administered orally
Drug: BGM0504
Number of treatment adverse events
The relationship of each adverse event tothe investigational product was assessed by the investigator
Time frame: 11 weeks
Pharmacokinetic endpoint: Concentration of BGM0504 in plasma
Time frame: 11 weeks
Change in fasting weight at week 11
Time frame: 11 weeks
Ran from Aug 2025 to primary completion in Mar 2026, 7 months.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
Primary completion moved twice since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, last on Oct 19, 2026.
Completion moved once since we started tracking on Sep 25, 2026: May 2026 → Jul 2026, on Oct 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BGM0504
BrightGene Bio-Medical Technology Co., Ltd. →